Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice

被引:103
作者
Knight, V
Koshkina, NV
Waldrep, JC
Giovanella, BC
Gilbert, BE
机构
[1] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA
[2] St Josephs Hosp, Stehlin Fdn Canc Res, Houston, TX USA
[3] Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA
关键词
aerosol; liposome; cancer; camptothecin; 9-nitrocamptothecin;
D O I
10.1007/s002800050965
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To test the anticancer properties of the water-insoluble derivative of camptothecin, 9-nitrocamptothecin (9-NC) against human breast, colon and lung cancer xenografts in nude mice when administered in liposome aerosol. Methods: The drug was formulated with dilauroylphosphatidylcholine and nebulized in a particle size of 1.6 mu m +/- 2.0 mass median diameter to deliver doses of usually less than 200 mu g/kg daily, 5 days per week. 9-NC liposome aerosols were generated with a Aerotech II nebulizer (CIS-USA) flowing at 10 l/min from a compressed air source and delivered to mice in sealed plastic cages or in a nose-only exposure chamber. Results: Tumor growth was greatly reduced or tumors were undetectable after several weeks of treatment. Colon tumor was least responsive. 9-NC was better than the parent compound, camptothecin, also water-insoluble, tested by aerosol in a similar liposomal preparation. Equivalent doses of 9-NC liposome preparations administered by mouth were substantially without effect while there was some effect, but limited, of the liposome preparation given intramuscularly. Conclusions: 9-NC liposome aerosol was strikingly effective in the treatment of three human cancer xenografts growing subcutaneously over the thorax in nude mice at doses much smaller than those traditionally used in mice administered by other routes.
引用
收藏
页码:177 / 186
页数:10
相关论文
共 33 条
[1]  
ALVAREZ FG, 1997, AM J RESP CRIT CARE, V155, pA659
[2]   LIPID BILAYER PARTITIONING AND STABILITY OF CAMPTOTHECIN DRUGS [J].
BURKE, TG ;
MISHRA, AK ;
WANI, MC ;
WALL, ME .
BIOCHEMISTRY, 1993, 32 (20) :5352-5364
[3]   PREFERENTIAL BINDING OF THE CARBOXYLATE FORM OF CAMPTOTHECIN BY HUMAN SERUM-ALBUMIN [J].
BURKE, TG ;
MI, ZH .
ANALYTICAL BIOCHEMISTRY, 1993, 212 (01) :285-287
[4]   Chemistry of the camptothecins in the bloodstream - Drug stabilization and optimization of activity [J].
Burke, TG .
CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 :29-31
[5]   Current perspectives on camptothecins in cancer treatment [J].
Dancey, J ;
Eisenhauer, EA .
BRITISH JOURNAL OF CANCER, 1996, 74 (03) :327-338
[6]   ANTITUMOR EFFECT OF LIPOSOME-INCORPORATED CAMPTOTHECIN IN HUMAN-MALIGNANT XENOGRAFTS [J].
DAOUD, SS ;
FETOUH, MI ;
GIOVANELLA, BC .
ANTI-CANCER DRUGS, 1995, 6 (01) :83-93
[7]   Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro [J].
EricksonMiller, CL ;
May, RD ;
Tomaszewski, J ;
Osborn, B ;
Murphy, MJ ;
Page, JG ;
Parchment, RE .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (05) :467-472
[8]   MEASUREMENT OF RESPIRATORY VOLUME FOR VIRUS RETENTION STUDIES IN MICE [J].
FAIRCHILD, GA .
APPLIED MICROBIOLOGY, 1972, 24 (05) :812-818
[9]   Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins [J].
Fleury, F ;
Kudelina, I ;
Nabiev, I .
FEBS LETTERS, 1997, 406 (1-2) :151-156
[10]  
Gilbert B.E., 1996, SEMIN PEDIAT INFECT, V7, P148, DOI [10.1016/s1045-1870(96)81012-0, DOI 10.1016/S1045-1870(96)81012-0]